Literature DB >> 30539728

Durable response to first-line nivolumab in a patient with oligometastatic PD-L1 positive nasopharyngeal cancer.

S Cabezas-Camarero1, F Puebla2, A I Subhi-Issa3, J Sanz-Ortega3, Pedro Pérez-Segura4.   

Abstract

Entities:  

Keywords:  First-line; Nasopharyngeal cancer; Nivolumab; Oligometastatic disease; PDL1; Platinum-induced neurotoxicity; Radiotherapy

Mesh：

Substances：

Year:  2018        PMID： 30539728     DOI： 10.1016/j.oraloncology.2018.10.019

Source DB:  PubMed          Journal:  Oral Oncol        ISSN： 1368-8375            Impact factor:   5.337


× No keyword cloud information.
  2 in total

Review 1.  Current Immune-Related Molecular Approach in Combating Nasopharyngeal Cancer.

Authors:  Soehartati A Gondhowiardjo; Marlinda Adham; Henry Kodrat; Demak Lumban Tobing; I Made Haryoga; Agustinus Gatot Dwiyono; Yoseph Adi Kristian
Journal:  World J Oncol       Date:  2019-09-20

2.  Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.

Authors:  Ryusuke Hori; Shogo Shinohara; Tsuyoshi Kojima; Hiroki Kagoshima; Morimasa Kitamura; Ichiro Tateya; Hisanobu Tamaki; Yohei Kumabe; Ryo Asato; Hiroyuki Harada; Yoshiharu Kitani; Takashi Tsujimura; Keigo Honda; Kazuyuki Ichimaru; Koichi Omori
Journal:  Cancers (Basel)       Date:  2019-09-06       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.